Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients

Table 2

Clinical features of four patients with hepatic irAE.

Case	Age	Sex	Primary lesion	ICIs	Duration of ICIs until liver injury, days	Clinical symptoms	The pattern of liver injury	Histologic pattern of liver injury	Therapy
1	75	M	Hypopharyngeal	NIVO	14	Loss of appetite	Hepatocellular	Panlobular hepatitis; Moderate fibrosis	Steroid + UDCA
2	52	M	Renal	NIVO + IPI	63	Fever	Hepatocellular	Panlobular hepatitis	Steroid + UDCA
3	72	M	Esophageal	NIVO	360	No symptoms	Mixed	Portal >zone 3 hepatitis	Steroid
4	58	M	Gastric	NIVO	56	Abdominal pain	Cholestatic	Portal hepatitis cholangitis	Steroid + UDCA

irAEs: immune-related adverse events; ICIs: immune checkpoint inhibitors; NIVO: nivolumab; IPI: ipilimumab; UDCA: ursodeoxycholic acid.